

HD BANK (HDB) 2022年8月1日

# 持有 - 有望

目標價格上漲:+37%收盤29/07/2022價格:24.150 越南盾12 個月目標價格:33.100 越南盾

#### 股票價格與 VN-Index 之間的相關性



2,1 tỷ USD
5,6 triệu USD
2.012 triệu
70%
16,9%
16,6%
11,1x
6,6x
1,4x
4,6%
0,0%

## 源:Fiinpro, 元大越南

HDB 的業務業績	2022 年第 二季度	% QoQ	% YoY
淨利潤收入(億越南盾)	4.551	13%	31%
淨費用收入(億越南盾)	835	37%	54%
總營業收入調整 (億越 南盾)	5.478	9%	31%
合約費用 (億越南盾)	2.033	6%	21%
預防(億越南盾)	772	15%	62%
PATMI (越南盾)	2.079	8%	34%
NPL (%)	1,33%	-24bps	+12bps
LLR (%)	93%	+17ppt	+5ppt
CASA (%)	12,3%	-30bps	+1,8ppt
CAR (%)	14,9%		

源:企業數據,元大越南

## 分析專家:

Tran Tanh

+84 28 3622 6868 ext 3874

tanh.tran@yuanta.com.vn

Bloomberg code: YUTA

# HD Bank (HDB)

# 強勁增長的信貸和費用收入

## 事件

HDB 報告稱,由於淨利息收入和淨費用收入增加,母公司在 2022 年第二季度的稅後利潤 (PATMI) 為 2 兆 1,000 億越南盾(環比增長 8% / 同比增長 34%)。 2022 年上半年(1H22), PATMI 達到 4 兆越南盾(同比增長 28%),完成我們在 2022 年預測的 53%。

## 焦點

自年初以來信貸增長 +15%。受強勁信貸增長的推動,2022 年第二季度的淨利息收入環比增長 +13% / 同比增長 31%。1H22 淨利息收入為 8 兆 6,000 億越南盾(同比增長 26%)。我們估計平均總資產的淨利潤率(NIM)為 4.8%(環比增長 +50bps/同比增長 +55bps)。

**2022 年第二季度淨費用收入**為 8,350 億越南盾(環比增長 37% / 同比增長 54%)。1H22 淨費用收入同比增長 68% 至 1 兆 4,000 億越南盾,主要來自銀行保險和非現金支付服務收取的費用。

**外匯業務**環比增長 249% / 同比增長 89%, 達到 800 億越南盾。與此同時, 證券交易/投資在 2022 年第二季度僅錄得 70 億越南盾(環比下降 -98% / 同比下降 -94%) 的淨利潤。

2022 年第二季度的運營費用為 2 兆越南盾(環比增長 6% / 同比增長 21%)。 2022 年第二季度調整後的成本/收入比率 (CIR) 為 37% (環比下降 1ppt/ 同比下降 3ppt)。該銀行表示,成本降低主要是由於數字化。1H22 運營費用同比增長+19%,達到 4 兆越南盾。

**2022 年第二季度的預防為 7,720 億越南盾(環比增長 15% / 同比增長 62%)。** 1H22 預防達到 1 兆 4,000 億越南盾(同比增長 58%)。

我們估計 2022 年第二季度 HDB 的壞賬覆蓋率 (LLR) 為 93% (環比增長 17ppt/同比增長 5ppt)。公佈的壞賬率 (NPL) 下降至 1.33% (環比下降 24bps/同比增長 12%)。

CASA 環比增長 3% / 同比增長 26%,在 2022 年第二季度末達到 26 兆越南盾。 HDB 的 CASA率在 2022 年第二季度末為 12.3% (環比下降 30bps/同比增長 1.8ppt)。

**堅實的資本**。資本充足率(CAR)為 14.9%。HDB 預計通過股票股息方式將銀行的註冊資本增加至 25 % 3,000 億越南盾,派息率為 25%。

## 觀點

**我們預計費用收入(來自銀行保險)**在 2H22 和未來幾年仍將是 HDB 利潤的主要驅動力。

隨著 NPL 率下降和 LLR 率上漲,**資產質量穩定**。與資本有限的銀行相比,**充滿的資金**可能會幫助 HDB 獲得更高的信用額度。

CASA 率相當低,這是在資本成本上漲的背景下的劣勢。

**HDB 的 P/B 2022E 為 1.4 倍**,高於行業中值 1.3 倍,而 2022 年 ROE (21%) 對應 於行業平均水平。

## ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ARE LOCATED IN APPENDIX A.

Yuanta does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

# Appendix A: Important Disclosures

#### Analyst Certification

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

#### Ratings Definitions

BUY: We have a positive outlook on the stock based on our expected absolute or relative return over the investment period. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile. We recommend investors add to their position.

HOLD-Outperform: In our view, the stock's fundamentals are relatively more attractive than peers at the current price. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile.

HOLD-Underperform: In our view, the stock's fundamentals are relatively less attractive than peers at the current price. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile.

SELL: We have a negative outlook on the stock based on our expected absolute or relative return over the investment period. Our thesis is based on our analysis of the company's outlook, financial performance, catalysts, valuation and risk profile. We recommend investors reduce their position.

Under Review: We actively follow the company, although our estimates, rating and target price are under review.

Restricted: The rating and target price have been suspended temporarily to comply with applicable regulations and/or Yuanta policies.

Note: Yuanta research coverage with a Target Price is based on an investment period of 12 months. Greater China Discovery Series coverage does not have a formal 12 month Target Price and the recommendation is based on an investment period specified by the analyst in the report.

#### Global Disclaimer

© 2022 Yuanta. All rights reserved. The information in this report has been compiled from sources we believe to be reliable, but we do not hold ourselves responsible for its completeness or accuracy. It is not an offer to sell or solicitation of an offer to buy any securities. All opinions and estimates included in this report constitute our judgment as of this date and are subject to change without notice.

This report provides general information only. Neither the information nor any opinion expressed herein constitutes an offer or invitation to make an offer to buy or sell securities or other investments. This material is prepared for general circulation to clients and is not intended to provide tailored investment advice and does not take into account the individual financial situation and objectives of any specific person who may receive this report. Investors should seek financial advice regarding the appropriateness of investing in any securities, investments or investment strategies discussed or recommended in this report. The information contained in this report has been compiled from sources believed to be reliable but no representation or warranty, express or implied, is made as to its accuracy, completeness or correctness. This report is not (and should not be construed as) a solicitation to act as securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on such business in that jurisdiction.

Yuanta research is distributed in the United States only to Major U.S. Institutional Investors (as defined in Rule 15a-6 under the Securities Exchange Act of 1934, as amended and SEC staff interpretations thereof). All transactions by a US person in the securities mentioned in this report must be effected through a registered broker-dealer under Section 15 of the Securities Exchange Act of 1934, as amended. Yuanta research is distributed in Taiwan by Yuanta Securities Investment Consulting. Yuanta research is distributed in Hong Kong by Yuanta Securities (Hong Kong) Co. Limited, which is licensed in Hong Kong by the Securities and Futures Commission for regulated activities, including Type 4 regulated activity (advising on securities). In Hong Kong, this research report may not be redistributed, retransmitted or disclosed, in whole or in part or and any form or manner, without the express written consent of Yuanta Securities (Hong Kong) Co. Limited.

Taiwan persons wishing to obtain further information on any of the securities mentioned in this publication should contact: Attn: Research Yuanta Securities Investment Consulting 4F, 225,

Section 3 Nanking East Road, Taipei 104

Taiwan

Hong Kong persons wishing to obtain further information on any of the securities mentioned in this publication should contact: Attn: Research Yuanta Securities (Hong Kong) Co. Ltd 23/F, Tower 1, Admiralty Centre 18
Harcourt Road,
Hong Kong

Korean persons wishing to obtain further information on any of the securities mentioned in this publication should contact: Head Office Yuanta Securities Building
Euljiro 76 Jung-gu
Seoul, Korea 100-845

## Tel: +822 3770 3454

Indonesia persons wishing to obtain further information on any of the securities mentioned in this publication should contact: Attn: Research PT YUANTA SECURITIES INDONESIA

(A member of the Yuanta Group) Equity

Tower, 10th Floor Unit EFGH SCBD Lot

Jl. Jend. Sudirman Kav. 52-53 Tel:

(6221) - 5153608 (General)

Thailand persons wishing to obtain further information on any of the securities mentioned in this publication should contact: Research

#### department

Yuanta Securities (Thailand) 127 Gaysorn Tower, 16th floor Ratchadamri Road, Pathumwan Bangkok 10330

Vietnam persons wishing to obtain further information on any of the securities mentioned in this publication should contact: Research

## department

Yuanta Securities (Vietnam) 4th Floor, Saigon Centre Tower 1, 65 Le Loi Boulevard, Ben Nghe Ward, District 1, HCMC, Vietnam

# YUANTA SECURITIES NETWORK



#### YUANTA SECURITIES VIETNAM OFFICE

Head office: 4th Floor, Saigon Centre, Tower 1, 65 Le Loi Boulevard, Ben Nghe Ward, District 1, HCMC, Vietnam

## Institutional Research

## Matthew Smith, CFA

Head of Research

Tel: +84 28 3622 6868 (ext. 3815) matthew.smith@yuanta.com.vn

Tam Nguyen Analyst

(Property)

Tel: +84 28 3622 6868 (ext. 3874) tam.nguyen@yuanta.com.vn

## Di Luu

Analyst (Banks)

Tel: +84 28 3622 6868 (3874)

di.luu@yuanta.com.vn

## Binh Truong

Deputy Head of Research (O&G, Energy) Tel:

+84 28 3622 6868 (3845)

binh.truong@yuanta.com.vn

### Tanh Tran

Deputy Manager (Banks)

Tel: +84 28 3622 6868 (3874)

tanh.tran@yuanta.com.vn

## Institutional Sales

# Anh Nguyen

Sales Trader Supervisor

Tel: +84 28 3622 6868 (ext. 3909)

anh.nguyen2@yuanta.com.vn

## Dat Bui Sales

Trader

Tel: +84 28 3622 6868 (ext. 3941)

## Trung Nguyen

Sales Trader

Tel: +84 28 3622 6868 (ext. 3890)

trung.nguyen1@yuanta.com.vn

Vi Truong Sales

Trader

Tel: +84 28 3622 6868 (ext. 3940)

dat.bui@;	yuanta.com.vn
-----------	---------------

vi.truong@yuanta.com.vn